Literature DB >> 1638527

Adriamycin: protection from cell death by removal of extracellular drug.

P Vichi1, T R Tritton.   

Abstract

Adriamycin is a cytotoxic drug which has enjoyed considerable success in the treatment of cancer. This agent has a bewildering variety of biological effects both within and on the surface of cells exposed to drug, and it has proved difficult to unambiguously assign a single mechanism of action. In this report we are able to separate intracellular and extracellular actions by taking advantage of the complete lack of Adriamycin-induced cytotoxicity at low temperature. For example, cells exposed to 100 microM Adriamycin at 0 degree C are not killed by the drug, even though this concentration is orders of magnitude higher than the concentration needed to cause 100% cell death at 37 degrees C. If cells exposed to 100 microM Adriamycin at 0 degree C are shifted to fresh drug-free medium at 37 degrees C, there is a time-dependent decrease in survival. However, if the drug-free medium contains calf thymus DNA (1.5 mg/ml) to act as a reservoir for Adriamycin binding of effluxed drug, there is no ensuing cytotoxicity. Thus, the results show that no matter how much drug is present inside the cell, there must also be extracellular drug available for membrane interaction in order to initiate nuclear DNA damage and the cytotoxic cascade.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1638527

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Hormesis: a conversation with a critic.

Authors:  Edward J Calabrese
Journal:  Environ Health Perspect       Date:  2009-06-09       Impact factor: 9.031

2.  Lack of integrin alpha1beta1 leads to severe glomerulosclerosis after glomerular injury.

Authors:  Xiwu Chen; Gilbert Moeckel; Jason D Morrow; Dominic Cosgrove; Raymond C Harris; Agnes B Fogo; Roy Zent; Ambra Pozzi
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

3.  Response to adriamycin of transplasma membrane electron transport in adriamycin-resistant and nonresistant HL-60 cells.

Authors:  D J Morré; D M Morré; L Y Wu
Journal:  J Bioenerg Biomembr       Date:  1994-02       Impact factor: 2.945

4.  Continuous in situ electrochemical monitoring of doxorubicin efflux from sensitive and drug-resistant cancer cells.

Authors:  C Yi; M Gratzl
Journal:  Biophys J       Date:  1998-11       Impact factor: 4.033

Review 5.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 6.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

7.  Use of oligonucleotides to define the site of interstrand cross-links induced by Adriamycin.

Authors:  S M Cutts; D R Phillips
Journal:  Nucleic Acids Res       Date:  1995-07-11       Impact factor: 16.971

8.  Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes.

Authors:  Tom C Karagiannis; Ann J E Lin; Katherine Ververis; Lisa Chang; Michelle M Tang; Jun Okabe; Assam El-Osta
Journal:  Aging (Albany NY)       Date:  2010-10       Impact factor: 5.682

9.  Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma.

Authors:  J Vaage; D Donovan; P Uster; P Working
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Intratumoral injection of an adriamycin immunoconjugate against human pancreatic cancer xenografts.

Authors:  Y Kondo; Y S Chung; T Sawada; A Inui; Y Yamashita; K Hirayama; B Nakata; J J Ho; Y S Kim; M Sowa
Journal:  Jpn J Cancer Res       Date:  1995-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.